Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Fallopian Tube Carcinoma”

415 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 415 results

Large-scale testing (Phase 3)Ended earlyNCT02641639
What this trial is testing

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian Cancer
Mateon Therapeutics 70
Testing effectiveness (Phase 2)Study completedNCT00017017
What this trial is testing

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01264432
What this trial is testing

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Who this might be right for
Adult Solid NeoplasmPeritoneal CarcinomatosisRecurrent Fallopian Tube Carcinoma+2 more
National Cancer Institute (NCI) 34
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Study completedNCT01402271
What this trial is testing

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
European Organisation for Research and Treatment of Cancer - EORTC 88
Testing effectiveness (Phase 2)UnknownNCT04375956
What this trial is testing

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Study completedNCT00045175
What this trial is testing

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
University Health Network, Toronto 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Very early researchStudy completedNCT01747798
What this trial is testing

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Mayo Clinic 10
Testing effectiveness (Phase 2)Study completedNCT00939809
What this trial is testing

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Brenner Tumor+7 more
Gynecologic Oncology Group 31
Testing effectiveness (Phase 2)Study completedNCT00390234
What this trial is testing

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Who this might be right for
Fallopian Tube CancerFemale Reproductive CancerOvarian Carcinosarcoma+9 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT01248962
What this trial is testing

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Memorial Sloan Kettering Cancer Center 146
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT00030446
What this trial is testing

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
NCIC Clinical Trials Group 50
Very early researchStudy completedNCT02111941
What this trial is testing

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid TumorFallopian Tube Mucinous Neoplasm+20 more
Mayo Clinic 19
Testing effectiveness (Phase 2)Ended earlyNCT00522301
What this trial is testing

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT00671788
What this trial is testing

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Gynecologic Oncology Group 35
Not applicableLooking for participantsNCT05236686
What this trial is testing

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group 94
Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Next Page